Guys, I thank you for all your fantastic contributions, some insightful comments you made!
Durability or efficacy/acuity seem joined at the hip; and who knows (as often the case in biotech) what the future holds? Gene editing alternatives may still be a long way off so I strongly believe we have a safeish potential to gain x2 to x3 from here.
What matters most? Acuity or Duration? What if Opthea was wrong?, page-11
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $403.8M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.5¢ | 36.0¢ | $606.6K | 1.610M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 75584 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 33006 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |